Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung Cancer
Shots:
- The P-III study evaluating Rybrevant (bispecific Ab targeting EGFR and MET) + lazertinib vs osimertinib and lazertinib alone in 1074 patients with LA or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or substitution mutations
- The trial met its 1EPs & showed a significant & clinical improvement in PFS, demonstrated a safety profile consistent with prior reported data on the combination while the planned interim OS analysis showed a trend favoring the combination therapy vs Osimertinib
- The company plans to submit these results at an upcoming scientific congress incl. additional detail on select 2EPs. Rybrevant received approval from health authorities in the EU as well as other markets globally
Ref: Janssen | Image: Janssen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
